Skip to content

Amylyx Pharmaceuticals

US · AMLX #2392 by market cap Listed 2022
26.02 -0.18 -0.69%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 26.50 +1.15%
After-hours 25.55 -1.81%
39.6613.0126.022026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on AMLX?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +28.7% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 10.2% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days B → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability F

How much profit the business keeps from each dollar of sales and capital.

Gross margin -42.6% Better than 1%
Operating margin -292.6% Better than 5%
Net margin -345.4% Better than 4%
Return on equity -61.6% Better than 8%
Return on invested capital -64.5% Better than 4%
Momentum B

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -32.7% Better than 16%
6-month return 91.6% Better than 99%
12-month return (ex latest month) 85.4% Better than 93%
Distance below 52-week high 36.8% Better than 32%
Financial Health B-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 14.3x Better than 96%
Debt to assets 1.8% Better than 89%
Interest coverage -17.5x Better than 10%
Free cash flow / net income 21.7% Better than 6%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 77.7% Better than 78%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -14.10%
1M -9.56%
3M -34.39%
6M +91.18%
YTD +115.40%
1Y +91.75%
3Y +101.55%

Key statistics

Price & volume

Prev close
26.20
Open
25.64
Day range
25.52 - 26.40
Avg price
26.01
Volume
1.14M
Turnover
29.54M
Amplitude
3.36%
52-week range
10.83 - 41.14

Valuation

P/E
-17.01
P/E (TTM)
-18.20
P/B
4.44
EPS
-1.53
Net profit
-196.70M
Net assets
753.76M

Share structure

Market cap
3.35B
Float cap
2.88B
Shares out
128.56M
Float shares
110.59M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2022-01-07
52-week range 50% of range
10.83 41.14

36.8% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-10.81M net over the window

Short interest

Shares short
12.82M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Amylyx Pharmaceuticals (AMLX)?

Amylyx Pharmaceuticals last traded at 26.02. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Amylyx Pharmaceuticals's market cap?

About 3.35B.

What is the P/E ratio of Amylyx Pharmaceuticals?

The trailing twelve-month P/E is -18.20, below its own 5-year average of 23.86 — toward the bottom of its historical range (2.55% percentile). See the Valuation tab for the full history.

Does Amylyx Pharmaceuticals pay a dividend?

Amylyx Pharmaceuticals does not currently pay a regular dividend.

Is Amylyx Pharmaceuticals a buy according to analysts?

The consensus of 9 analysts is a Buy rating, with an average 12-month price target of 46.25, which implies 77.7% upside from the current price. This is not investment advice.

What is Amylyx Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Amylyx Pharmaceuticals a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 20:02:24 · For reference only, not investment advice and not tailored to your situation.

Amylyx Pharmaceuticals discussion 0 comments

Add a comment